Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic

被引:18
作者
Bennett, S. [1 ]
Soreide, K. [4 ,5 ]
Gholami, S. [6 ]
Pessaux, P. [8 ]
Teh, C. [9 ,10 ,11 ]
Segelov, E. [12 ,13 ]
Kennecke, H. [7 ]
Prenen, H. [14 ]
Myrehaug, S. [2 ]
Callegaro, D. [1 ,15 ]
Hallet, J. [1 ,3 ]
机构
[1] Univ Toronto, Dept Surg, Toronto, ON, Canada
[2] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
[3] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[4] Stavanger Univ Hosp, Dept Gastrointestinal Surg, Bergen, Norway
[5] Univ Bergen, Dept Clin Med, Bergen, Norway
[6] Univ Calif Davis, Dept Surg, Div Surg Oncol, Davis, CA 95616 USA
[7] Virginia Mason Canc Inst, Seattle, WA USA
[8] Inst Hosp Univ Strasbourg, Dept Surg, Strasbourg, France
[9] St Lukes Med Ctr, Inst Surg, Quezon City, Philippines
[10] Makati Med Ctr, Dept Surg, Makati, Philippines
[11] Natl Kidney & Transplant Inst, Dept Gen Surg, Makati, Philippines
[12] Monash Univ, Melbourne, Vic, Australia
[13] Monash Hlth, Melbourne, Vic, Australia
[14] Univ Hosp Antwerp, Dept Oncol, Antwerp, Belgium
[15] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Milan, Italy
关键词
COVID-19; coronavirus; hepatobiliary cancer; HCC; metastases; cholangiocarcinoma; gallbladder carcinoma; COLORECTAL LIVER METASTASES; STEREOTACTIC BODY RADIOTHERAPY; UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA; INCIDENTAL GALLBLADDER CANCER; TRANSFUSION RISK SCORE; LONG-TERM SURVIVAL; DRUG-ELUTING BEAD; HEPATOCELLULAR-CARCINOMA; RADIOFREQUENCY ABLATION; HEPATIC RESECTION;
D O I
10.3747/co.27.6785
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective We aimed to review data about delaying strategies for the management of hepatobiliary cancers requiring surgery during the COVID-19 pandemic. Background Given the COVID-19 pandemic, many jurisdictions, to spare resources, have limited access to operating rooms for elective surgical activity, including cancer, thus forcing deferral or cancellation of cancer surgeries. Surgery for hepatobiliary cancer is high-risk and particularly resource-intensive. Surgeons must critically appraise which patients will benefit most from surgery and which ones have other therapeutic options to delay surgery. Little guidance is currently available about potential delaying strategies for hepatobiliary cancers when surgery is not possible. Methods An international multidisciplinary panel reviewed the available literature to summarize data relating to standard-of-care surgical management and possible mitigating strategies to be used as a bridge to surgery for colorectal liver metastases, hepatocellular carcinoma, gallbladder cancer, intrahepatic cholangiocarcinoma, and hilar cholangiocarcinoma. Results Outcomes of surgery during the COVID-19 pandemic are reviewed. Resource requirements are summarized, including logistics and adverse effects profiles for hepatectomy and delaying strategies using systemic, percutaneous and radiation ablative, and liver embolic therapies. For each cancer type, the long-term oncologic outcomes of hepatectomy and the clinical tools that can be used to prognosticate for individual patients are detailed. Conclusions There are a variety of delaying strategies to consider if availability of operating rooms decreases. This review summarizes available data to provide guidance about possible delaying strategies depending on patient, resource, institution, and systems factors. Multidisciplinary team discussions should be leveraged to consider patient- and tumour-specific information for each individual case.
引用
收藏
页码:E501 / E511
页数:11
相关论文
共 110 条
[1]   Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis [J].
Al-Adra, D. P. ;
Gill, R. S. ;
Axford, S. J. ;
Shi, X. ;
Kneteman, N. ;
Liau, S. -S. .
EJSO, 2015, 41 (01) :120-127
[2]   A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group [J].
Al-Shamsi, Humaid O. ;
Alhazzani, Waleed ;
Alhuraiji, Ahmad ;
Coomes, Eric A. ;
Chemaly, Roy F. ;
Almuhanna, Meshari ;
Wolff, Robert A. ;
Ibrahim, Nuhad K. ;
Chua, Melvin L. K. ;
Hotte, Sebastien J. ;
Meyers, Brandon M. ;
Elfiki, Tarek ;
Curigliano, Giuseppe ;
Eng, Cathy ;
Grothey, Axel ;
Xie, Conghua .
ONCOLOGIST, 2020, 25 (06) :E936-E945
[3]   Solitary colorectal liver metastasis - Resection determines outcome [J].
Aloia, TA ;
Vauthey, JN ;
Loyer, EM ;
Ribero, D ;
Pawlik, TM ;
Wei, SH ;
Curley, SA ;
Zorzi, D ;
Abdalla, EK .
ARCHIVES OF SURGERY, 2006, 141 (05) :460-466
[4]  
American College of Surgeons (ACS), 2020, COVID 19 EL CAS TRIA
[5]  
American College of Surgeons (ACS), 2020, POINT OF CAR TRIAG T
[6]  
[Anonymous], 2020, J NATL COMPR CANC NE
[7]   Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer [J].
Azizi, Alexander A. ;
Lamarca, Angela ;
Valle, Juan W. .
CHINESE CLINICAL ONCOLOGY, 2019, 8 (04)
[8]   Nomogram to predict overall survival after gallbladder cancer resection in China [J].
Bai, Yi ;
Liu, Zhi-Song ;
Xiong, Jian-Ping ;
Xu, Wei-Yu ;
Lin, Jian-Zhen ;
Long, Jun-Yu ;
Miao, Fei ;
Huang, Han-Chun ;
Wan, Xue-Shuai ;
Zhao, Hai Tao .
WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (45) :5167-5178
[9]   Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations [J].
Bartlett, David L. ;
Howe, James R. ;
Chang, George ;
Crago, Aimee ;
Hogg, Melissa ;
Karakousis, Giorgos ;
Levine, Edward ;
Maker, Ajay ;
Mamounas, Eleftherios ;
McGuire, Kandace ;
Merchant, Nipun ;
Shibata, David ;
Sohn, Vance ;
Solorzano, Carmen ;
Turaga, Kiran ;
White, Richard ;
Yang, Anthony ;
Yoon, Sam .
ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (06) :1717-1720
[10]   Validation of clinical risk score for colorectal liver metastases resected in a contemporary multicenter cohort [J].
Beamish, Paul ;
Lemke, Madeline ;
Li, Jennifer ;
Dixon, Elijah ;
Abraham, Mauro T. ;
Alejandro, Roberto Hernandez ;
Bennett, Sean ;
Martel, Guillaume ;
Karanicolas, Paul J. .
HPB, 2017, 19 (08) :675-681